MedPath

CARISOPRODOL

These highlights do not include all the information needed to use CARISOPRODOL tablets, USP safely and effectively. See full prescribing information for CARISOPRODOL tablets, USP. Carisoprodol tablets, USP for Oral use CIV Initial U.S. Approval: 1959

Approved
Approval ID

78d4da6a-17d7-1d95-e053-2991aa0a8336

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 22, 2021

Manufacturers
FDA

NuCare Pharmaceuticals,Inc.

DUNS: 010632300

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

CARISOPRODOL

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code68071-4610
Application NumberANDA203374
Product Classification
M
Marketing Category
C73584
G
Generic Name
CARISOPRODOL
Product Specifications
Route of AdministrationORAL
Effective DateFebruary 22, 2021
FDA Product Classification

INGREDIENTS (8)

CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
CELLULOSE, MICROCRYSTALLINEInactive
Code: OP1R32D61U
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
POVIDONEInactive
Code: FZ989GH94E
Classification: IACT
CARISOPRODOLActive
Quantity: 350 mg in 1 1
Code: 21925K482H
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CARISOPRODOL - FDA Drug Approval Details